Maynard Um
-
-
-
-
-
-
-
Iovanace Biotherapeutics (IOVA) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
Iovance reports 52% response rate for Amtagvi in early melanoma treatment
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Perform Rating on Iovanace Biotherapeutics (IOVA)
-
-
-
-
-
-
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
-
-
-
-
-
-
IOVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action
-
-
-
-
-
-
-
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
-
-
-
-
-
-
IOVA FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class
-
443,926 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

